MONMOUTH JUNCTION, N.J., March 17, 2020 /PRNewswire/ -- Tris Pharma, Inc., Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, amidst the uncertainty created by the COVID-19 pandemic, reiterated its commitment to the ADHD community by assuring ADHD patients, caregivers and health care professionals of the continuity of supply of its family of ADHD products. Specifically, Tris reminded the ADHD community that:
Additionally, Tris is proactively addressing the maintenance and potential increase of product availability by:
"We are honored to be entrusted with providing the highest quality prescription ADHD medications to our many patients affected by ADHD," said Ketan Mehta, Chief Executive Officer of Tris Pharma."We will continue to monitor the ever-changing pandemic environment and will adjust as necessary to meet the needs of our patients and their health care professionals."
Quillivant XR, QuilliChew ER, and Dyanavel XR are approved for treatment of ADHD in people 6 years and older. See products' Approved Use and Important Safety Information, including Boxed Warning about Abuse and Dependence, below.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines that address unmet patient needs. Tris has pioneered the delivery of long-acting liquid, chewable, orally-disintegrating, and film strip dosage forms that can accommodate the unique needs of a wide variety of patients. Tris' fully integrated research, manufacturing, medical and commercial facilities are located in Central New Jersey. For more information, please visit http://www.trispharma.com
APPROVED USE
Dyanavel XR, Quillivant XR, and QuilliChew ER are central nervous system (CNS) stimulant prescription medicinesused for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)in people 6 years and older. These medicines may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.
It is not known if Dyanavel XR, Quillivant XR, and QuilliChew ER are safe and effective in children under 6 years of age.
IMPORTANT SAFETY INFORMATION
Dyanavel XR, Quillivant XR, and QuilliChew ERare federally controlled substances (CII) because they can be abused or lead to dependence. Keep these medicinesin a safe place to prevent misuse and abuse. Selling or giving away these medicinesmay harm others and is against the law. Tell your doctor if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
Dyanavel XR, or Quillivant XR and QuilliChew ER,should not be taken if you or your child are allergic to amphetamine or methylphenidate hydrochloride, respectively, or any of the ingredients in these medicines, or are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI.
Dyanavel XR, Quillivant XR, and QuilliChew ERcan cause serious side effects. Tell the doctor:
Common side effects of amphetamine products include:
Common side effects of methylphenidate products include:
Talk to your doctor if you or your child have any side effects that bother you or do not go away.
Avoid drinking alcohol while taking Dyanavel XR, Quillivant XR, or QuilliChew ER.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch,or call 1-800-FDA-1088.
See Medication Guide and Full Prescribing Information for Dyanavel XR,Quillivant XR, and QuilliChew ER,including Boxed Warningabout Abuse and Dependence.
View original content:http://www.prnewswire.com/news-releases/quillivant-xr-quillichew-er-and-dyanavel-xr-are-100-made-in-the-usa-and-remain-consistently-supplied-during-covid-19-pandemic-301025268.html
SOURCE Tris Pharma, Inc.
Read more from the original source:
Quillivant XR, QuilliChew ER and Dyanavel XR are 100% Made in the USA and Remain Consistently Supplied During COVID-19 Pandemic - BioSpace
